OnKure Therapeutics, Inc. OKUR Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by OnKure Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: OnKure Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about OnKure Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is OnKure Therapeutics, Inc.'s financing cash flow?
- OnKure Therapeutics, Inc. (OKUR) reported financing cash flow of $146M in Q1 2026.
- How has OnKure Therapeutics, Inc.'s financing cash flow changed year-over-year?
- OnKure Therapeutics, Inc.'s financing cash flow increased by 189709.1% year-over-year, from -$77K to $146M.
- What is the long-term trend for OnKure Therapeutics, Inc.'s financing cash flow?
- Over 2 years (2021 to 2024), OnKure Therapeutics, Inc.'s financing cash flow has grown at a -6.3% compound annual growth rate (CAGR), from $132.41M to $116.13M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.